Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pharmacological differences and switching among anti-CGRP monoclonal antibodies: A narrative review.
Headache
January 2025
Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
Antibodies targeting either the calcitonin gene-related peptide (CGRP), such as galcanezumab, fremanezumab, and eptinezumab, or the receptor (erenumab) have been approved for the prevention of episodic and chronic migraine. Although widely used and generally effective, a proportion of patients discontinue treatment due to lack of efficacy. In both randomized controlled trials and observational studies, all anti-CGRP monoclonal antibodies (mAbs) have consistently demonstrated comparable efficacy and tolerability, suggesting a pharmacological class effect.
View Article and Find Full Text PDFMedication underuse in real-life practice: the impact of galcanezumab towards achieving very low frequency episodic migraine in a southeast Asian middle-income nation.
J Headache Pain
January 2025
Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, USA.
Background: Migraine progression, particularly from episodic to chronic migraine (CM), increases disease burden and healthcare costs. Understanding the new concept of "Medication Underuse Headache" should encourage the health care provider to consider early intervention with calcitonin gene-related peptide (CGRP) monoclonal antibodies. Galcanezumab given early in the course of the disease, may prevent migraine chronification and have a robust response, moreso than when initiated in later stages of migraine.
View Article and Find Full Text PDFCan ACR TI-RADS predict the malignant risk of medullary thyroid cancer?
J Clin Transl Endocrinol
March 2025
Department of Ultrasound, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, PR China.
Objectives: This study aimed to evaluate the diagnostic performance for medullary thyroid cancer (MTC) based on the 2017 Thyroid Imaging Reporting and Data System by the American College of Radiology (ACR TI-RADS) guideline, and the ability to recommend fine needle aspiration (FNA) for MTC.
Methods: Fifty-six MTCs were included, and 168 benign thyroid nodules (BTNs) and 168 papillary thyroid nodules (PTCs) were matched according to age. Ultrasound (US) features were reviewed according to ACR TI-RADS.
Background: The aim of this study was to explore the clinical application value of serum inflammatory markers in the diagnosis and treatment of benign prostatic hyperplasia (BPH) in elderly men.
Methods: From April 2023 through July 2023, 110 BPH patients and 120 healthy individuals who underwent examinations at our hospital were selected as study subjects. The concentrations of C-reactive protein (CRP), procalcitonin (PCT), serum amyloid A (SAA), complement 3 (C3), and complement 4 (C4) were measured in both groups.
Impact of Emergency Warning Nursing on CRP, PCT, TNF-α and Clinical Indicators in Patients with Acute Stress Disorder under Hierarchical Analysis.
Actas Esp Psiquiatr
January 2025
Clinical Teaching and Research Department, The Southwest Hospital of AMU, 400038 Chongqing, China.
Background: In emergency warning nursing, the pre-alert system significantly influences the biochemical markers and clinical outcomes of patients with Acute Stress Disorder. Therefore, this study applies hierarchical analysis to explore the impact of early warning nursing on crucial indicators such as C-reactive protein (CRP), procalcitonin (PCT), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and assess their clinical efficacy.
Methods: The study selected patients with acute stress disorder who were hospitalized in Southwest Hospital of Chongqing from December 2021 to December 2022, and collected data from 250 patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!